NovoCure Limited
Moat Score — NovoCure Limited
Total Moat Score
11 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | NovoCure holds hundreds of issued patents running through 2041 protecting Tumor Treating Fields, a therapeutic modality it created, and faces no FDA-approved competing device today, a genuinely rare first-mover position in oncology. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | All system components are outsourced to third-party manufacturing partners, and the company bears direct financial collection risk under its billing model, offering no structural cost advantage over a hypothetical competitor. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Optune Gio has secured national reimbursement in nine countries plus Medicare fee-for-service and broad U.S. private insurance coverage, but Optune Lua and Optune Pax still lack national reimbursement anywhere and are billed case-by-case, showing pricing power must be rebuilt indication by indication. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect; one patient's use of Optune does not increase its value to another patient. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Prescriber certification training requirements and established payer reimbursement pathways for Optune Gio create real switching friction against any future rival TTFields device, though these barriers reset for each newly launched indication. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | NovoCure essentially defined the TTFields category and operates as the only commercial-scale player, with its own filing noting only 'a few third parties' attempting to develop competing devices, none yet approved. |